The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Direct oral anticoagulants (DOACs) account for most oral anticoagulant use. DOAC-
associated bleeding events are commonly encountered in clinical practice and are …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Hereditary deficiency of antithrombin, a natural anticoagulant, causes a thrombophilia with a
high risk for venous thromboembolism. Guidance for laboratory testing to diagnose …

There is a laboratory and clinical need to know the impact of direct oral anticoagulants
(DOACs) on diagnostic tests to avoid misinterpretation of results. Although the regulatory …

Non‐vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor
dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and …

Thromboembolic diseases are one of the leading causes of morbidity and mortality
worldwide. For a long time, heparin and Vitamin K antagonist (VKA) drugs were used for …

Background Thrombin generation testing has been used to provide information on the
coagulation phenotype of patients. The most used technique is the calibrated automated …

For decades, oral anticoagulation has been based on vitamin K antagonist such as warfarin,
which requires pharmacodynamic (PD) drug monitoring to guide the therapy. The drug effect …

Abstract Purpose of Review The introduction of newer anticoagulants requires clinicians to
fully appreciate, interpret, and correctly apply the use of coagulation assays, such as the …